The FDA approved Amarin’s CVD risk-reducing drug, Vascepa, in 2019, having first approved it for triglyceride reduction in 2012. At a cost less than $60/year under my insurance plan, I began taking oral Vascepa capsules, off-label, with prescription in April 2013 at age 76(father died from 2nd heart attack at age 51 in 1959). Never obese, I have lost about 25 lbs while using 20% less LLY insulin to manage my T1-D since 2016. I now weigh the same as I did in my university years, 1955-1961.
PFE sells Vascepa in all Canadian provinces, per agreement.
AMRN’s share price, $0.90, is about even YTD. Share price was $18-25 in 2019. Shareholders will vote on a share repurchase plan in early April 2024 while waiting for revenue-driven earnings from Europe and Asia, and results from the Brave trial (Indication: Alzheimer’s ). Sarissa Capital holds ~ 9.9% of outstanding shares, and views Amarin as under-valued. Will AMRN share price out-perform share price of either LLY or NVO in 2024-2025 in % gain?
